Related Experiment Video
Updated: Aug 30, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Clinical impact of abciximab on long-term outcome after complex coronary angioplasty
Jasper S Wijpkema1, Gillian A J Jessurun, Ad J Van Boven
1Department of Cardiology, University Hospital Groningen, Groningen, The Netherlands.
Insights
Abciximab administration in percutaneous coronary interventions helps mitigate major adverse cardiac events (MACEs), particularly in complex lesions. This glycoprotein IIb/IIIa receptor antagonist use equalizes outcomes between simple and complex lesions, supporting its use in complex cases.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Glycoprotein IIb/IIIa receptor antagonists like abciximab are crucial for reducing major adverse cardiac events (MACEs) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
- Assessing the impact of abciximab based on lesion complexity and procedural complications is essential for optimizing patient care.
Purpose of the Study:
- To evaluate the administration of abciximab in relation to lesion complexity and periprocedural complications.
- To determine if abciximab use influences the relationship between lesion complexity and MACEs.
Main Methods:
- A study included 357 patients with 435 de novo lesions, categorized as simple (A, B1) or complex (B2, C) using the ACC/AHA lesion complexity system.
- Abciximab was administered to patients with unstable complex lesions or simple lesions experiencing a complicated course.
- Major adverse cardiac events (MACEs) were tracked over a 9-month follow-up period.
Main Results:
- Patients receiving abciximab presented with higher lesion complexity, more dissections, stent use, and involved vessels.
- The abciximab group also showed higher angina class, lower pre-stenting TIMI flow, and longer inflation times.
- Despite these factors, MACE incidence was similar between groups (16.2% with abciximab vs. 17.3% without).
- Crucially, lesion complexity correlated with MACE in the no-abciximab group but not in the abciximab group, indicating abciximab neutralizes this risk factor.
Conclusions:
- Abciximab administration effectively neutralizes the increased risk of MACE associated with complex coronary lesions.
- The drug equalizes outcomes between simple and complex lesions, suggesting its benefit in complex percutaneous coronary interventions.
- Abciximab should be considered, especially in unstable and complex percutaneous coronary interventions to improve patient outcomes.
Abstract:
Glycoprotein IIb/IIIa receptor antagonists, such as abciximab, are used to reduce major adverse cardiac events (MACEs) in patients undergoing percutaneous transluminal coronary angioplasty. The goal of this study was to evaluate the administration of abciximab in relation to lesion complexity and periprocedural complications. A total of 357 patients with 435 de novo lesions were included in this study. Lesions were divided into simple (type A and type B1) and complex (type B2 and type C) lesions according to the American College of Cardiology/American Heart Association Task Force lesion complexity system. Abciximab was given to unstable complex lesions and simple lesions with a periprocedural unstable complicated course. The overall incidence of MACE during the 9-month follow-up period was 17.0%. Patients treated with abciximab had a higher lesion complexity (P < 0.001), dissections (P = 0.014), stents (P < 0.001), and vessels involved (P < 0.001). in addition, the abciximab group was characterized by a higher angina NYHA class (P = 0.005), lower TIMI flow prior to stenting (P = 0.01), and a longer total inflation time (P = 0.006). Despite these clinical differences, the occurrence of MACE within the abciximab group was slightly less than in the group without abciximab (16.2% and 17.3%, respectively). Lesion complexity was directly related to MACE in the group that did not receive abciximab (simple and stable complex lesions; P = 0.04). On the other hand, in subjects treated with abciximab, lesion complexity was not related to a higher incidence of MACE (P = 0.76). The use of abciximab equalizes the difference in outcome between simple and complex lesions. Therefore, abciximab should be advocated especially in unstable and complex percutaneous coronary interventions.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies